Metabolism Based Diagnosis and Precision Medicine for Autism Spectrum Disorders
Metabolism Based Diagnosis and Precision Medicine for Autism Spectrum Disorders
Video of presentation at The National TACA Autism Conference – East Coast in Atlanta, Georgia, March 2019.
In this video, Beth Donley shares her history as an autism mom as well as details about the NeuroPointDX NPDX ASD test, which is a blood test that can identify about 30% of children with autism spectrum disorder with an increased risk of an ASD diagnosis. This means that 3 in 19 kids with autism spectrum disorder could receive an earlier diagnosis, get interventions sooner, and potentially receive more precise treatment suggestions from their doctors, based on the information about their own metabolism.
As the parents of an adult son on the spectrum, Beth Donley, who helped develop the test, knows firsthand how important receiving an early diagnosis and a precise treatment plan is to helping our children reach their potential. This knowledge was the motivation behind her quest to develop a test that can diagnose children with autism as early as 18 months.
Behavioral tests can lead to an ASD diagnosis in children as young as 24 months old, but the average age of diagnosis in the United States is more than 4 years. Being told to “wait and see” can be frustrating for parents. It’s tough to wait it out when your child needs help.
The NeuroPointDX NPDX ASD test offers an opportunity to identify and refer children at risk of an autism diagnosis earlier so they can receive treatment sooner.
Adapted from a post on @TheAutismCommunityinAction Facebook page.